Clinical trial for centronuclear myopathy given the green light in the UK

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

The drug company Dynacure has announced today that UK regulators have approved its UNITE-CNM phase I/II clinical trial. UNITE-CNM will be a first-in-human study of the drug candidate DYN101, and will enrol patients greater than 16 years of age with X-linked and autosomal dominant centronuclear myopathy. It is expected to begin in the second half of 2019.

For more information, read Dynacure’s press release.

If you have any questions about this news story or any other centronuclear myopathy research, please contact the MDUK Research Line on 020 7803 4813 or email

Keep in touch